DarioHealth to Report Third Quarter 2024 Results on Thursday, November 7th

DRIO 10.23.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-07
Name of Upcoming Event:Earnings Call
Full Press ReleaseSEC FilingsOur DRIO Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - DarioHealth Announces $25.6M Private Placement Positioning the Company to Execute on Strategy Aiming to Reach Operational Cash Flow Positive Run Rate by the End of 2025
  • 01.14.2025 - DarioHealth Expands GLP-1 Solution with Prescribing Capabilities through Collaboration with MediOrbis, Targeting Employers and Direct-to-Consumer Markets
  • 11.21.2024 - Dario Signs Four New Employer Contracts Across Full Product Suite

Recent Filings

  • 01.22.2025 - 8-K Current report
  • 01.22.2025 - EX-99.1 EX-99.1
  • 01.17.2025 - D Notice of Exempt Offering of Securities

Press Releases

DarioHealth to Report Third Quarter 2024 Results on Thursday, November 7th

Oct 23, 2024

  • Photos(1)

DarioHealth_Logo

Wednesday, October 23, 2024 (8:30am)

DarioHealth Corp. Logo

  • Download Hi-Res
CLOSE

Company to host conference call and webcast at8:30am ET

NEW YORK,Oct. 23, 2024/PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a global leader in digital health, announced today that it will release its financial results for the 3rdquarter ended September 30th, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Thursday, November 7th, 2024, before the market opens.

DarioHealth Corp. Logo

Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call.

Conference Call Details

Date: Thursday, November 7th,8:30am ET

Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international)

Call meTM: https://emportal.ink/3SOTLAn

Participants can use the dial-in numbers above and be answered by an operator OR click the Call meTM link for instant telephone access to the event. This link will be made active 15 minutes prior to scheduled start time.

Webcast link: https://viavid.webcasts.com/starthere.jsp?ei=1685062&tp_key=51068b0c30

Participants are asked to dial in approximately 10 minutes prior to the start of the event. A replay of the call will be available approximately two hours after completion of the conference call through Thursday, November 21, 2024. To listen to the replay, dial 1-844-512-2921 (domestic) or 1-412-317-6671 (international) and use replay passcode 1131131.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a global digital health company dedicated to transforming the way people manage chronic conditions through its user-centric, multi-condition digital therapeutics platform. Dario's comprehensive platform leverages data analytics, AI, and personalized coaching to deliver continuous care for diabetes, hypertension, musculoskeletal health, weight management, and behavioral health. By empowering individuals to take control of their health through behavior change, Dario is revolutionizing the digital health landscape.

For more information, visithttp://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected date of its earnings release. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for DarioTM as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280

DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922

Media Contact:
Scott Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630

Logo -https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

SOURCE DarioHealth Corp.


Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com